title: Autologous and allogenic natural cell mediated cytotoxicity at the single cell level: divergent effects of interferons and interleukin 2 on binding and lysis.
abstract: In order to evaluate their divergent effects on binding and lysis of the NCMC, rH IFN-alpha and rH IL-2 were used for the in vitro-preincubation of normal donors' PBL, which were then tested as effector cells against K562 and the long-term cultured melanoma cell line RIMA in the SCCA. Both lymphokines significantly augmented the cytolysis of K562 without relevant influence on the conjugate formation. However, against RIMA IFN-alpha additionally amplified the binding affinity. This in keeping with the other authors' opinion that IFNs have target-specific effects at the single cell level, with the principal activation of already conjugated pre-killer cells against all the target cell lines tested. We performed a therapy-follow-up of the i.p. administration of rH IFN-gamma to patients with ovarian carcinomas in vivo. With the SCCA we detected a significant correlation of the duration of therapy with the autologous cytotoxicity in the ascitic compartment. In one case the increase of this parameter was even exponential. However, the countercurrent trend of the conjugate formation delayed and reduced the activation of the autologous total killer activity. This relative stagnation resulted in the inadequate clinical response of two patients. Moreover, we observed a discrepancy in the development of the autologous and allogeneic SCCA-parameters suggesting strong effects of the peritumorally administered IFN directly on the effusion tumor cells.
authors.affiliation: Institute for Applied and Experimental Oncology, University of Vienna, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Klappacher
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins